Karyopharm signals $1B annual U.S. peak revenue opportunity for selinexor in myelofibrosis ...

Management reiterated full-year 2025 guidance for total revenue of $140 million to $155 million and U.S. XPOVIO net product revenue of $110 million to $120 million. Macomber updated, "We are lowering ...